Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

if they had a CC, we could have got some color on whether Fusilev will lose any more significant sales and what kind of trajectory Evomela is on.

Well, we’re not going to hear it from Spectrum management but but at least we get some color from Ligand

and Spectrum’s product Evomela is showing good momentum in sales growth following its launch earlier this year

So what will 'good momentum' translate into additional sales for the 4th Q? Will it be 2M? 3M? 4M? I'll go w 3M which will translate to about 9M or 50% growth of the drug next Q. Why, I'm sure there will be additional P&T (pharmacy and therapeutics) committees which only meet once or twice a year that will be approving it in their formularies which will translate into additional sales. I have no doubt that we will be north of 50M in sales next year for Evomela as a result of the convenience of its much longer stability profile and lack of 'PG' in preparing the solution for injection. And being the only per label drug for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with MM, and the additional indication for the palliative treatment of patients with MM for whom oral therapy (like Celgene's Revlimid and Pomalyst) is not appropriate can't hurt.